Dear Sir/Madam, Pursuant to your email dated 11th September, 2025 please find the attached revised outcome of Board Meeting held on 14th August, 2025. Thanking You.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Prism Medico and Pharmacy Ltd approved the unaudited standalone financial results for the quarter ended 30 June 2025 (Q1 FY26), along with a clean Limited Review Report from the auditors. Revenue from operations jumped sharply to Rs 158.87 lakhs in Q1 FY26, up from just Rs 7.28 lakhs in Q1 FY25. The company reported a net profit of Rs 65.73 lakhs versus Rs 4.15 lakhs in the same quarter last year, marking a strong turnaround compared to the full FY25 audited loss of Rs 2.13 lakhs. Total expenses stood at Rs 93.84 lakhs and basic EPS was Rs 0.0108. This filing is a revised version of the earlier outcome submitted to BSE, following clarifications sought via email on 11 September 2025.
The sharp jump in revenue and a swing to profitability versus last year signals a meaningful business improvement for the quarter, which is positive for shareholders. However, the company operates on a very small base and the figures should be read with that scale in mind.